Background: The ability of pretreatment laboratory markers of acute-phase inflammatory reactions like serum albumin level (SAL), hemoglobin (Hb), and absolute blood cell counts to predict complete pathological response (CPR) to neoadjuvant chemoradiotherapy (NACRT) in patients with locally advanced rectal cancer (LARC) has not yet been fully studied. Methods: We retrospectively examined the relation between SAL, Hb and absolute blood cell counts, and CPR rates in 140 LARC patients treated with NACRT. Results: Univariate analysis showed a significantly higher probability of CPR to NACRT in patients with clinical stage (CS) III LARC who had SAL >3.5 mg/dl (OR = 2.39; p = 0.04) and a neutrophil-to-lymphocyte ratio (NLR) value <5 (OR = 2.86; p = 0.03). The relation of CPR with SAL (OR = 2.11; p = 0.048) and NLR (OR = 2.54; p = 0.04) was confirmed by multivariate analysis in the same subset of patients. None of the parameters studied predicted CPR in patients with CS II disease. Patients who achieved CPR to NACRT had a higher probability of 5-year overall survival (HR 0.48; p = 0.01) and 5-year disease-free survival (HR 0.33; p = 0.003). Conclusions: Our data indicate that SAL >3.5 mg/dl and NLR <5 may be positively related to CPR after NACRT in patients with CS III LARC. Hypoalbuminemia and a high NLR may be considered an indication for a more aggressive approach to NACRT and postoperative adjuvant chemotherapy in this subset of patients. This hypothesis requires confirmation in a randomized study.

Keywords:
Rectal cancer, Pretreatment inflammatory response, Neoadjuvant chemoradiotherapy
1.
Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2.
Cammà C, Giunta M, Fiorica F, et al: Preoperative radiotherapy for resectable rectal cancer: a meta-analysis. JAMA 2000;284:1008-1015.
3.
Sauer R, Becker H, Hohenberger W, et al: Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731-1740.
4.
Gérard JP, Conroy T, Bonnetain F, et al: Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006;24:4620-4625.
5.
Bosset JF, Collette L, Calais G, et al: Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006;355:1114-1123.
6.
Collette L, Bosset JF, den Dulk M, et al: Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J Clin Oncol 2007;25:4379-4386.
7.
Dworak O, Keilholz L, Hoffmann A: Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 1997;12:19-23.
8.
Chan AKP, Wong A, Jenken D, et al: Posttreatment TNM staging is a prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 2005;61:665-677.
9.
Rödel C, Martus P, Papadoupolos T, et al: Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005;23:8688-8696.
10.
Wiig JN, Larsen SG, Dueland S, Giercksky KE: Clinical outcome in patients with complete pathologic response (pT0) to preoperative irradiation/chemo-irradiation operated for locally advanced or locally recurrent rectal cancer. J Surg Oncol 2005;92:70-75.
11.
Stipa F, Chessin DB, Shia J, et al: A pathologic complete response of rectal cancer to preoperative combined-modality therapy results in improved oncological outcome compared with those who achieve no downstaging on the basis of preoperative endorectal ultrasonography. Ann Surg Oncol 2006;13:1047-1053.
12.
Bujko K, Michalski W, Kepka L, et al: Association between pathologic response in metastatic lymph nodes after preoperative chemoradiotherapy and risk of distant metastases in rectal cancer: an analysis of outcomes in a randomized trial. Int J Radiat Oncol Biol Phys 2007;67:369-377.
13.
Quah HM, Chou JF, Gonen M, et al: Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation. Cancer 2008;113:57-64.
14.
Cooper EH, Stone J: Acute phase reactant proteins in cancer. Adv Cancer Res 1979;30:1-44.
15.
De Mello J, Struthers L, Turner R, et al: Multivariate analyses as aids to diagnosis and assessment of prognosis in gastrointestinal cancer. Br J Cancer 1983;48:341-348.
16.
Kern KA, Norton JA: Cancer cachexia. J Parenter Enteral Nutr 1988;12:286-298.
17.
Koea JB, Shaw JH: The effect of tumor bulk on the metabolic response to cancer. Ann Surg 1992;215:282-288.
18.
McMillan DC, Wotherspoon HA, Fearon KC, et al: A prospective study of tumor recurrence and the acute-phase response after apparently curative colorectal cancer surgery. Am J Surg 1995;170:319-322.
19.
Crumley ABC, McMillan DC, McKernan M, et al: Evaluation of an inflammation-based prognostic score in patients with inoperable gastro-oesophageal cancer. Br J Cancer 2006;94:637-641.
20.
Sasaki A, Iwashita Y, Shibata K, et al: Prognostic value of preoperative peripheral blood monocyte count in patients with hepatocellular carcinoma. Surgery 2006;139:755-764.
21.
Vaupel P, Mayer A, Hockel M: Impact of hemoglobin level on tumour oxygenation: the higher the better? Strahlenther Oncol 2006;182:63-71.
22.
Hoff CM, Hansen HS, Overgaard M, et al: The importance of hemoglobin level and effect of transfusion in HNSCC patients treated with radiotherapy - results from the randomized DAHANCA 5 study. Radiother Oncol 2011;98:28-33.
23.
Sasaki K, Kawai K, Tsuno NH, et al: Impact of preoperative thrombocytosis on the survival of patients with primary colorectal cancer. World J Surg 2012;36:192-200.
24.
AJCC Cancer Staging Manual (ed 7). New York, Springer, 2010.
25.
Fisher RA: On the interpretation of χ2 from contingency tables, and the calculation of p. J Royal Stat Soc 1922;85:87-94.
26.
LaValley MP: Logistic regression. Circulation 2008;117:2395-2399.
27.
Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
28.
Walsh SR, Cook EJ, Goulder F, et al: Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 2005;91:181-184.
29.
Sasaki A, Kai S, Endo Y, et al: Prognostic value of preoperative peripheral blood monocyte count in patients with colorectal liver metastasis after liver resection. J Gastrointest Surg 2007;11:596-602.
30.
Ishizuka M, Nagata H, Takagi K, Kubota K: Influence of inflammation-based prognostic score on mortality of patients undergoing chemotherapy for far advanced or recurrent unresectable colorectal cancer. Ann Surg 2009;250:268-272.
31.
Ding PR, An X, Zhang RX, Fang YJ, et al: Elevated preoperative neutrophil to lymphocyte ratio predicts risk of recurrence following curative resection for stage IIA colon cancer. Int J Colorectal Dis 2010;25:1427-1433.
32.
Qiu MZ, Yuan ZY, Luo HY, et al: Impact of pretreatment hematologic profile on survival of colorectal cancer patients. Tumour Biol 2010;31:255-260.
33.
Chua W, Charles KA, Baracos VE, et al: Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer 2011;104:1288-1295.
34.
Carruthers R, Tho LM, Brown J, et al: Systemic inflammatory response is a predictor of outcome in patients undergoing preoperative chemoradiation for locally advanced rectal cancer. Colorectal Dis 2012;14:e701-e707.
35.
Kitayama J, Yasuda K, Kawai K, et al: Circulating lymphocyte number has a positive association with tumor response in neoadjuvant chemoradiotherapy for advanced rectal cancer. Radiat Oncol 2010;5:47.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.